The Survey Research Center (SRC) was founded in April 1991 and has been a Cancer Center Shared Resource since 2003. Its purpose is to facilitate the conduct of high quality science through the provision of excellent consultation and service delivery for all aspects of survey design and conduct for Mayo Clinic Cancer Center (MCCC) investigators. Under the leadership of Dr. Timothy Beebe (since 2004), the SRC strives for excellence by providing high quality and efficient service delivery by deploying "state of the science" methods in the areas of instrument development, sampling, mailing, telephoning, response tracking, instrument processing, and data file preparation. The SRC is the only Mayo Clinic facility offering this comprehensive set of services. The SRC has conducted over 2,000 survey-based studies since its inception. Over the course of the past grant period (2008-2013), the SRC has consulted on -192 separate survey projects. Of these, 45 were led by MCCC investigators representing a wide range of programs (n = 10) with Women's Cancer, Cancer Control and Prevention (CPC), Genetic Epidemiology and Risk Assessment (GERA), and Hematologic Malignancies being among the most frequent users. Overall, ~ 60% of MCCC investigators using SRC services did so with funding supplied by peer-reviewed and competitive extramural grant support. For MCCC investigators, this resource has and will continue to provide expert consultation and support for the conduct of survey research relevant to their research endeavors. The initial consultations and assistance with proposal development, overall research design, and questionnaire design are done at no charge to MCCC members due to the support provided by the CCSG. For all other services (questionnaire formatting, web survey programming, editorial review, printing, mailings, telephoning, updating the tracking system, data entry, data analysis, and reporting) MCCC investigators are given priority access to SRC services and resources. MCCC investigators are given priority access to SRC services and resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682939
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$61,495
Indirect Cost
$22,861
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9
Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34
Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70
Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43
Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508
Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7
Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8
Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97

Showing the most recent 10 out of 340 publications